Research Peptides in Australia: Legal Status and TGA Regulatory Framework

The Therapeutic Goods Administration (TGA) is the Australian Government agency responsible for regulating therapeutic goods — medicines, medical devices, biologicals, and related products. The TGA operates under the Therapeutic Goods Act 1989 (Cth) and enforces the Poisons Standard (SUSMP), which schedules chemical substances according to their risk profile and intended use.

A substance falls under TGA jurisdiction when it is presented, represented, or likely to be regarded as suitable for therapeutic use — that is, for use in or on humans for the purpose of preventing, diagnosing, curing, or alleviating a disease, ailment, defect, or injury. The key operative concept is intended and represented use. Substances that are supplied, labelled, and documented strictly for in-vitro laboratory research or scientific study, and that are not represented as suitable for human therapeutic use, occupy a different regulatory space from approved therapeutic goods.

This distinction is important for understanding how research-grade peptides fit within the Australian regulatory framework.

The Australian Poisons Standard (SUSMP) assigns chemical substances to schedules based on their pharmacological properties, toxicity, and the level of control required for safe use. Schedule 4 (S4) — Prescription Only Medicine — covers substances that require medical oversight for safe therapeutic use.

Approved pharmaceutical peptides that have undergone TGA registration for specific therapeutic indications are scheduled accordingly. For example, semaglutide injection (Ozempic, Wegovy) is a Schedule 4 substance when supplied as a registered therapeutic good for the treatment of type 2 diabetes or chronic weight management. Tirzepatide (Mounjaro) is similarly scheduled. These approved medicines require a valid prescription from a registered Australian medical practitioner to be legally dispensed through a pharmacy.

Research-grade peptides — synthetic compounds not formulated or represented for human therapeutic use — are subject to a different analysis. A compound is not automatically Schedule 4 simply because a pharmaceutical analogue exists; the scheduling applies to the substance as represented for therapeutic use. Unformulated research compounds supplied with COA documentation, sold for laboratory research purposes only, and not represented for human use are not therapeutic goods in the TGA sense and are therefore not dispensed under the Poisons Standard in the same manner as approved medicines.

"Research use only" (RUO) is a designation used across laboratory supply industries globally to indicate that a compound is supplied for scientific investigation, not for therapeutic, diagnostic, or clinical use. In the Australian context, this designation is legally significant because it affects how a substance is characterised under the Therapeutic Goods Act.

When a supplier clearly labels, documents, and represents compounds as being for laboratory research purposes only — and does not make therapeutic claims, does not provide dosing instructions for human use, and does not represent the product as suitable for administration to humans — the product is not being supplied as a therapeutic good. Suppliers operating in this space are not registered TGA manufacturers or sponsors, and their products are not entered on the Australian Register of Therapeutic Goods (ARTG).

Researchers purchasing such compounds are responsible for ensuring their intended use is consistent with the research-only representation. Australian researchers working in licensed laboratory environments, conducting in-vitro or preclinical studies, operate within an established framework for using research-grade chemical compounds that are not therapeutic goods.

GLP-1 receptor agonist peptides — including Semaglutide, Tirzepatide, and Retatrutide — are active areas of pharmaceutical research. TGA-registered pharmaceutical versions of Semaglutide and Tirzepatide exist as Schedule 4 prescription medicines for specific therapeutic indications.

Retatrutide, as of 2026, has not received TGA registration or marketing approval in Australia. It remains an investigational compound with Phase 3 clinical trials underway (NCT06184373). Research-grade Retatrutide synthesised for laboratory investigation of GLP-1/GIP/Glucagon receptor pharmacology is not equivalent to an unapproved therapeutic good — it is a research chemical in the same category as other unregistered peptide compounds.

For Semaglutide and Tirzepatide, the situation is nuanced. The TGA-scheduled designation attaches to the compound as represented for therapeutic use. Research-grade material supplied for pharmacological investigation, receptor binding studies, or in-vitro research — not for human administration — is not being supplied as the Schedule 4 pharmaceutical product. The compound's chemical identity is the same; the regulatory characterisation depends on the use representation.

RetaLABS supplies all GLP-1 peptides as research-grade compounds for laboratory research use only. No therapeutic claims are made. All products are accompanied by Certificate of Analysis (COA) documentation confirming identity and purity.

The Australian Border Force (ABF) applies Customs legislation and works alongside the TGA on importation of therapeutic goods. Importing therapeutic goods without TGA authorisation is a serious offence. However, the same research-use distinction that applies domestically is relevant at the border.

Research chemicals that are not scheduled or controlled substances under Australian law (Customs (Prohibited Imports) Regulations 1956 or the relevant state and territory legislation) and that are not being imported as therapeutic goods are not subject to the TGA import restrictions in the same manner as prescription medicines.

Peptides that are not narcotics, psychotropics, or controlled substances under Australian federal law — and that are not being imported for therapeutic use — do not trigger the specific import prohibition categories. However, customs declarations must accurately represent the contents, and any misrepresentation is an offence regardless of the substance involved.

RetaLABS is an Australian-based supplier. All products stocked by RetaLABS are dispatched domestically via Australia Post Express from within Australia. There are no international customs implications for domestic purchases from RetaLABS.

A Certificate of Analysis (COA) is the primary quality and compliance document for research-grade peptides. A COA from a reputable third-party laboratory confirms the compound's identity (typically via mass spectrometry), purity (HPLC, usually expressed as a percentage), and the absence of specified contaminants.

For Australian researchers, COA documentation serves multiple functions: it verifies that the compound received matches the stated specification; it provides a documented chain of custody consistent with laboratory research procurement practices; and it supports the research-use characterisation of the supply by demonstrating the product is laboratory-grade material, not a consumer therapeutic product.

RetaLABS publishes COA documentation for all products. Researchers should retain COA records as part of standard laboratory procurement documentation. When in doubt about the regulatory status of any compound for a specific research application, consulting with an Australian regulatory affairs specialist or legal adviser is recommended.

Australian drug and poison scheduling operates at both federal and state/territory levels. The federal Poisons Standard provides a national framework, but state and territory governments legislate their own poisons and therapeutic goods laws, which must be at least as restrictive as the federal standard.

For research institutions — universities, NATA-accredited laboratories, and licensed research facilities — state and territory research exemptions and licensing frameworks apply. Researchers operating within licensed facilities should ensure their procurement and handling of research chemicals complies with their institution's ethics approvals, biosafety protocols, and relevant state legislation.

Individual researchers sourcing compounds for personal research outside a licensed institutional context should be aware that their state or territory's specific legislation may affect what they are permitted to hold and use. The general principle — that research-grade compounds not represented for therapeutic use occupy a different regulatory space from approved medicines — applies broadly, but the specifics vary by jurisdiction and circumstance.

• TGA regulation attaches to therapeutic use — compounds not represented for human therapeutic use are not therapeutic goods under the Therapeutic Goods Act 1989
• Schedule 4 applies to approved medicines — the prescription-only designation applies to registered pharmaceutical products supplied for therapeutic purposes, not to research-grade material supplied for laboratory investigation
• Retatrutide is unregistered — it is an investigational compound with no TGA-approved pharmaceutical product, making the research-grade/therapeutic distinction straightforward
• COA documentation matters — retain COA records as standard laboratory procurement documentation
• RetaLABS ships domestically — no international importation involved; all orders dispatched within Australia via Express Post
• Seek professional advice for specific situations — this article provides a general overview of the regulatory framework; it is not legal advice. Researchers with specific compliance questions should consult an Australian regulatory affairs specialist

For questions about specific products or documentation, contact RetaLABS directly. All products are supplied for laboratory research use only — not for human consumption, therapeutic use, or veterinary application.